Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4512)
°¨¿°Áúȯ (322)
°ñÁúȯ Ä¡·á (48)
´ç´¢º´ (164)
¹é½Å (169)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (49)
ºñó¹æ ÀǾàǰ (149)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (179)
½Å¾à°³¹ß (1306)
¾ÏÄ¡·á (856)
¾à¹°Àü´Þ (179)
ÀǾàǰ ±ÔÁ¦È¯°æ (105)
Á¤½ÅÁúȯ (88)
Á¦³×¸¯ ÀǾàǰ (116)
Á¦¾àȸ»çºÐ¼® (488)
󹿾à (128)
Áö¿ªº°°Ë»ö
ÃâÆÇ»ç¿¡¼­ ã±â

Á¤½ÅÁúȯ ½ÃÀåÁ¶»çº¸°í¼­

Á¤½ÅÁúȯ ½ÃÀåÀ» Á¶»ç ºÐ¼®ÇÑ ÀÚ·á·Î ½ÃÀå ±Ô¸ð, »ê¾÷ ºÐ¼®, ÇâÈÄ ½ÃÀå ¿¹Ãø µîÀÇ ³»¿ëÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù.
º¸°í¼­¿¡ µû¶ó¼­ ÁÖ¿ä ±â¾÷ ºÐ¼®, °æÀïȯ°æ ºÐ¼®, ¿¬±¸°³¹ß ÇöȲ, ¿µ¾÷ Àü·«, ±â¾÷ Á¦ÈÞ ÇöȲÀ» Æ÷ÇÔÇÏ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù.

»ó¼¼ºÐ·ù
Á¦¸ñ°Ë»ö
1 - 25 ¸®ºä (Àüü£º 88 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
Alzheimer disease - new drugs, markets and companies
»óǰÄÚµå :70927
¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ Ä¡·á¾à °³¹ß µ¿Çâ ¹× °ü·Ã ±â¾÷ÀÇ Á¤º¸ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Jain Pharmabiotech
ÆäÀÌÁö¼ö  
Major Depressive Disorder (MDD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :222282
¼¼°èÀÇ ¿ì¿ïÁõ(MDD : Major Depressive Disorder) Ä¡·áÁ¦ ½ÃÀåÀ» Á¶»ç ºÐ¼®Çϰí, MDD °³¿ä¿Í Ä¡·á¹ý, ÁÖ¿ä ±¹°¡º° ½ÃÀå±Ô¸ð¿Í 2018³â±îÁö ¼ºÀå ¿¹Ãø, Ãâ½Ã Á¦Ç° ÇÁ·ÎÆÄÀÏ, °³¹ß ÆÄÀÌÇÁ¶óÀÎ, ÇâÈÄ ½ÃÀå Àü¸Á µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 100
Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :217929
¿ì¿ïÁõ(Depression) Ä¡·á¹ýÀÇ ¿¬±¸ °³¹ß Ãֽе¿Çâ Á¶»ç¿Í °ü·Ã ½ÃÀåÀÇ ÇâÈÄ ¿¹ÃøÀ» ½Ç½ÃÇϰí, Áúº´ °³¿ä¿Í ´ëó¹ý, ¼¼°è ¹× ÁÖ¿ä 7°³±¹ÀÇ ½ÃÀå±Ô¸ð ÃøÁ¤°ú ¿¹Ãø(2005-2018³â), °æÀï ±¸Á¶, ÀÓ»ó½ÃÇè ÁøÇà »óȲ¿¡ °üÇÑ ÆÄÀÌÇÁ¶óÀÎ Æò°¡, ÇâÈÄ ½ÃÀå µ¿Çâ°ú ±â¾÷ Àü·«¿¡ °üÇÑ Àü·«Àû °íÂû µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 95
Autistic Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :217225
ÀÚÆóÀå¾ÖÀÇ °³¿ä¿Í Áø´Ü, Ä¡·á¹ý, Ä¡·áÁ¦ ½ÃÀåÀÇ ±Ô¸ð¿Í 2018³â±îÁöÀÇ ¿¹Ãø, ÁÖ¿ä ½ÃÀ庰 µ¿Çâ, °³¹ß ÆÄÀÌÇÁ¶óÀÎ, Âü¿©±â¾÷ °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 67
Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 - 2015)
»ùÇÃ
»óǰÄÚµå :208006
¼¼°èÀÇ Á¤½ÅºÐ¿­Áõ ½ÃÀåÀ» Á¶»çºÐ¼®ÇßÀ¸¸ç, ÁÖ¿ä±¹ÀÇ ÇöÀç ÀÌȯÀα¸¿Í ÇâÈÄ Àü¸Á, ÁÖ¿ä Ä¡·áÁ¦ ºê·£µå, ÁÖ¿ä µ¥Æ÷Á¦(Depot Formulations)ÀÇ ¸ÅÃâ ½ÇÀû ¹× ¿¹Ãø, ÆÄÀÌÇÁ¶óÀξà Àü¸Á, ÁÖ¿ä ±â¾÷ °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 850
¹ßÇàÀÏ 2011³â 08¿ù
¸®¼­Ä¡»ç Renub Research
ÆäÀÌÁö¼ö 65 Pages
Epidemiology: Attention Deficit Hyperactivity Disorder - Adult prevalence continues to be under-reported
»ùÇÃ
»óǰÄÚµå :209098
ÁÖÀǷ°áÇÌ °úÀ×ÇൿÀå¾Ö(ADHD: Attention Deficit Hyperactivity Disorder)¿¡ ´ëÇÑ ÇâÈÄ 10³â°£ÀÇ ¿ªÇÐÀû ¿¹ÃøÀ» Æ÷ÇÔÇÑ ½ÃÀå µ¿Çâ, ¿ªÇÐÀû À§ÇèÀÎÀÚ, À¯·´ ¹× ¹Ì±¹, ÀϺ» µî Áö¿ªº° µ¿Ç⠵ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 08¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 33
»ùÇÃ
»óǰÄÚµå :208199
¿ì¿ïÁõ(Depression) ½ÃÀå¿¡ ÁøÃâÇÏ´Â ÁÖ¿ä ±â¾÷ÀÇ ºê·£µå ¼ö¸íÁÖ±â¿Í Æ÷Æ®Æú¸®¿À °ü¸® Àü·«¿¡ ´ëÇØ »ó¼¼ÇÏ°Ô ºÐ¼®Çϰí, °¢»çÀÇ Àü·« µ¿Çâ, ÇâÈÄÀÇ ±âȸ ¹× °úÁ¦ µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,800
¹ßÇàÀÏ 2011³â 08¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 40
Seroquel XR - Analysis and Estimates from 2007 to 2020
»ùÇÃ
»óǰÄÚµå :217360
Á¤½ÅºÐ¿­Áõ Ä¡·áÁ¦ÀÎ Seroquel XRÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» Á¶»çÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®°ú ÇâÈÄ ½ÃÀå °æÀï, ±â¾÷ °³¿ä¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 29
Invega Sustenna - Analysis and Forecasts from 2009 to 2020
»ùÇÃ
»óǰÄÚµå :217343
Á¤½ÅºÐ¿­Áõ Ä¡·áÁ¦ÀÎ Invega SustennaÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 30
Cariprazine - Analysis and Forecasts from 2013 to 2020
»ùÇÃ
»óǰÄÚµå :217342
Á¤½ÅºÐ¿­Áõ Ä¡·áÁ¦ÀÎ CariprazineÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 26
RG1678 - Analysis and Forecasts from 2014 to 2020
»ùÇÃ
»óǰÄÚµå :217338
Á¤½ÅºÐ¿­Áõ Ä¡·áÁ¦ÀÎ RG1678ÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 30
Abilify - Analysis and Estimates from 2002 to 2020
»ùÇÃ
»óǰÄÚµå :217336
Á¤½ÅºÐ¿­Áõ Ä¡·áÁ¦ÀÎ AbilifyÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» Á¶»çÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®°ú ÇâÈÄ ½ÃÀå °æÀï »óȲÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 32
Zyprexa - Analysis and Forecasts from 2002 to 2018
»ùÇÃ
»óǰÄÚµå :217334
Á¤½ÅºÐ¿­Áõ Ä¡·áÁ¦ÀÎ ZyprexaÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 32
Seroquel - Analysis and Estimates from 2002 to 2020
»ùÇÃ
»óǰÄÚµå :217330
Á¤½ÅºÐ¿­Áõ Ä¡·áÁ¦ÀÎ SeroquelÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» Á¶»çÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®°ú ÇâÈÄ ½ÃÀå °æÀï »óȲÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 32
Risperdal Consta - Analysis and Forecasts from 2003 to 2020
»ùÇÃ
»óǰÄÚµå :217329
Á¤½ÅºÐ¿­Áõ Ä¡·áÁ¦ÀÎ Risperdal ConstaÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 31
Clozapine - Analysis and Forecasts from 2002 to 2020
»ùÇÃ
»óǰÄÚµå :217327
Á¤½ÅºÐ¿­Áõ Ä¡·áÁ¦ÀÎ ClozapineÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 30
Geodon - Analysis and Forecasts from 2002 to 2017
»ùÇÃ
»óǰÄÚµå :217324
Á¤½ÅºÐ¿­Áõ Ä¡·áÁ¦ÀÎ Geodon/ZeldoxÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 29
Zicronapine - Analysis and Forecasts from 2014 to 2020
»ùÇÃ
»óǰÄÚµå :217322
Á¤½ÅºÐ¿­Áõ Ä¡·áÁ¦ÀÎ ZicronapineÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 28
Saphris - Analysis and Estimates from 2009 to 2020
»ùÇÃ
»óǰÄÚµå :217319
Á¤½ÅºÐ¿­Áõ Ä¡·áÁ¦ÀÎ SaphrisÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» Á¶»çÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®°ú ÇâÈÄ ½ÃÀå °æÀï »óȲÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 25
Invega - Analysis and Forecasts from 2007 to 2020
»ùÇÃ
»óǰÄÚµå :217312
Á¤½ÅºÐ¿­Áõ Ä¡·áÁ¦ÀÎ InvegaÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 29
Latuda - Analysis and Forecasts from 2011 to 2020
»ùÇÃ
»óǰÄÚµå :217310
Á¤½ÅºÐ¿­Áõ Ä¡·áÁ¦ÀÎ LatudaÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 32
Epidemiology: Bipolar Disorders - Population growth to mean more patients with bipolar disorders
»ùÇÃ
»óǰÄÚµå :206497
ÇâÈÄ 10³â°£ÀÇ Á¶¿ïÁõ¿¡ ´ëÇÑ ¿ªÇÐÀû ¿¹Ãø, Á¶¿ïÁõÀÇ À§ÇèÀÎÀÚ µî¿¡ ´ëÇØ Á¤¸®ÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 39
Special Report: Autism Spectrum Disorders--High Unmet Needs Create Significant Market Opportunities
»ùÇÃ
»óǰÄÚµå :203150
ÀÚÆó ¹üÁÖ¼º Àå¾Ö(ASD : Autism Spectrum Disorders)ÀÇ °³¿ä¿Í ¹Ì±¹ÀÇ 2020³â±îÁö 10³â°£ ¿ªÇÐ, Áø´Ü ±âÁØ, ½ÅÈï Ä¡·á¹ý µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 9,200
¹ßÇàÀÏ 2011³â 06¿ù
¸®¼­Ä¡»ç Decision Resources, Inc.
ÆäÀÌÁö¼ö  
R&D Trends: Attention-Deficit Hyperactivity Disorder - Growing pipeline indicates a trend towards adjunctive and adult therapy
»ùÇÃ
»óǰÄÚµå :203576
ÁÖÀÇ·Â °áÇÌ Àå¾Ö(ADHD)ÀÇ Ä¡·áÁ¦ ¿¬±¸°³¹ß¿¡ °üÇÑ Ãֽе¿Çâ°ú ÇâÈÄ 20³â µ¿¾È ¿¹»óµÇ´Â Ä¡·á ¹æ¹ýÀÇ º¯È­¸¦ Á¶»çºÐ¼®Çϰí Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,800
¹ßÇàÀÏ 2011³â 06¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 69
Product Profiles: Depression - Next generation vies for second-line patients
»ùÇÃ
»óǰÄÚµå :203196
¿ì¿ïÁõ(Depression) Ä¡·á¸¦ À§ÇÑ Ãâ½Ã ºê·£µå¿Í ÆÄÀÌÇÁ¶óÀÎ ¾àÁ¦ÀÇ µ¿ÇâÀ» ºÐ¼®Çϰí, ÀÓ»ó ¹× »ó¾÷Àû Ư¼º¿¡ °üÇÑ ºñ±³ ºÐ¼®, ÃÖ±ÙÀÇ ÀÓ»ó½ÃÇè µ¥ÀÌÅÍ, Ãâ½Ã ºê·£µåÀÇ ÇâÈÄ Àü¸Á°ú ¿ì¿ïÁõ Ä¡·áÀÇ ÃæÁ·µÇÁö ¾ÊÀº ¿å±¸(Unmet Needs) µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 11,400
¹ßÇàÀÏ 2011³â 06¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 221